Trials / Not Yet Recruiting
Not Yet RecruitingNCT06935175
A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in Patients With Advanced Hepatocellular Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 53 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study was designed to evaluate the efficacy and safety of SHR-1826 monotherapy or in combination with immunotherapy in the treatment of advanced hepatocellular cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1826 | SHR-1826 will be administrated per dose level in which the patients are assigned. |
| DRUG | SHR-1826 and immunotherapy combination therapy | SHR-1826 and immunotherapy will be administrated per dose level in which the patients are assigned. |
Timeline
- Start date
- 2025-05-01
- Primary completion
- 2027-05-31
- Completion
- 2028-05-31
- First posted
- 2025-04-20
- Last updated
- 2025-04-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06935175. Inclusion in this directory is not an endorsement.